These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12735912)

  • 1. Withdrawal of levodopa and other risk factors for malignant syndrome in Parkinson's disease.
    Hashimoto T; Tokuda T; Hanyu N; Tabata K; Yanagisawa N
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S25-30. PubMed ID: 12735912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A collaborative study on the malignant syndrome in Parkinson's disease and related disorders.
    Takubo H; Harada T; Hashimoto T; Inaba Y; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S31-41. PubMed ID: 12735913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders.
    Harada T; Mitsuoka K; Kumagai R; Murata Y; Kaseda Y; Kamei H; Ishizaki F; Nakamura S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S15-23. PubMed ID: 12735911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant syndrome in Parkinson's disease: concept and review of the literature.
    Mizuno Y; Takubo H; Mizuta E; Kuno S
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S3-9. PubMed ID: 12735909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome in advanced Parkinson's disease.
    Gordon PH; Frucht SJ
    Mov Disord; 2001 Sep; 16(5):960-2. PubMed ID: 11746631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention and treatment of malignant syndrome in Parkinson's disease: a consensus statement of the malignant syndrome research group.
    Ikebe S; Harada T; Hashimoto T; Kanazawa I; Kuno S; Mizuno Y; Mizuta E; Murata M; Nagatsu T; Nakamura S; Takubo H; Yanagisawa N; Narabayashi H
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S47-9. PubMed ID: 12735915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome in a patient with Parkinson's disease: a case study.
    Ward C
    J Neurosci Nurs; 2005 Jun; 37(3):160-2. PubMed ID: 16001822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome without neuroleptics.
    Ong KC; Chew EL; Ong YY
    Singapore Med J; 2001 Feb; 42(2):85-8. PubMed ID: 11358199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An interaction between levodopa and enteral nutrition resulting in neuroleptic malignant-like syndrome and prolonged ICU stay.
    Bonnici A; Ruiner CE; St-Laurent L; Hornstein D
    Ann Pharmacother; 2010 Sep; 44(9):1504-7. PubMed ID: 20628041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome.
    Gibb WR; Griffith DN
    Postgrad Med J; 1986 Jan; 62(723):59-60. PubMed ID: 3797365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroleptic malignant syndrome postoperative onset due to levodopa withdrawal.
    Young CC; Kaufman BS
    J Clin Anesth; 1995 Dec; 7(8):652-6. PubMed ID: 8747565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevention and treatment of malignant syndrome in patients with Parkinson's disease].
    Kuno S
    Nihon Rinsho; 2004 Sep; 62(9):1721-4. PubMed ID: 15462391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum creatine kinase is elevated in patients with Parkinson's disease: a case controlled study.
    Takubo H; Shimoda-Matsubayashi S; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S43-6. PubMed ID: 12735914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal.
    Friedman JH; Feinberg SS; Feldman RG
    JAMA; 1985 Nov; 254(19):2792-5. PubMed ID: 4057489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroleptic malignant syndrome after withdrawal of levopoda].
    Cedeno-Veloz B; Areosa Sastre A
    Rev Esp Geriatr Gerontol; 2018; 53(5):299-300. PubMed ID: 29628214
    [No Abstract]   [Full Text] [Related]  

  • 17. Neuroleptic malignant syndrome without neuroleptics.
    Parsa MA; Rohr T; Ramirez LF; Meltzer HY
    J Clin Psychopharmacol; 1990 Dec; 10(6):437-8. PubMed ID: 2286714
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy of methyprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
    Clarke CE
    J Neurol Neurosurg Psychiatry; 2004 Mar; 75(3):510-1; author reply 511. PubMed ID: 14966183
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroleptic malignant syndrome complicating levodopa withdrawal.
    Reutens DC; Harrison WB; Goldswain PR
    Med J Aust; 1991 Jul; 155(1):53-4. PubMed ID: 2067442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preface: Malignant syndrome in Parkinson's disease.
    Narabayashi H; Mizuno Y
    Parkinsonism Relat Disord; 2003 Apr; 9 Suppl 1():S1. PubMed ID: 12735908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.